Polaris Group (6550) AI Stock Analysis

Polaris Group

(TWSE:6550)

Select Model

Rating:37Underperform

Price Target:TWD 13.00▼(-3.70% Downside)

Action:initiatedcoverage

Date:11/10/26

The overall score is at the minimum of 37, reflecting a convergence of severe risks. The primary driver is the company's dire financial state, characterized by massive and growing cash burn, deep unprofitability, and a deteriorating balance sheet. This is compounded by a strongly bearish technical trend and a negative P/E ratio, leaving no fundamental or market-based support for the stock.

Positive Factors

Specialty drug development platformPolaris operates across the biopharmaceutical value chain rather than relying on a single development activity. Its oncology and specialty-therapy focus can support differentiated expertise, while commercialization and partnering capabilities provide multiple routes to turn drug programs into future revenue.

Negative Factors

Deepening net lossesLosses are expanding while profitability remains deeply negative, showing that current operations are not yet converting the company’s development platform into sustainable earnings. Continued deterioration can consume equity, reduce financial flexibility, and increase dependence on external funding.

Polaris Group (6550) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 6.35B
Dividend Yield: ―
Average Volume (3M): 675.53K
Price to Earnings (P/E): -1.5
Beta (1Y): 0.39
Revenue Growth: 6.15%
EPS Growth: -13.99%
Country: TW
Employees: 83,293
Sector: General
Sector Strength: 55
Industry: Biotechnology

Polaris Group Business Overview & Revenue Model

Company Description

Polaris Group, together with its subsidiaries, offers biotechnology, drug testing, and contract development and manufacturing services. The company engages in the research, development, manufacture and sale of new drugs. It develops ADI-PEG 20 for th...

Polaris Group Financial Statement Overview

Summary

Financial health is critically poor. The company is pre-revenue with a -97.2% net margin, deeply negative gross margins, and widening operating losses. Cash burn is severe, with free cash flow at -$3.19B, and the balance sheet is deteriorating due to rising leverage and shrinking equity. This represents an existential financial risk.

Income Statement

8Very Negative

Balance Sheet

35Negative

Cash Flow

10Very Negative

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	67.95M	40.60M	107.00M	7.48M	6.44M	15.04M
Gross Profit	-420.06M	-270.32M	-76.92M	-137.90M	-141.86M	-150.62M
EBITDA	-2.06B	-2.50B	-2.17B	-1.41B	-990.13M	-570.97M
Net Income	-3.79B	-3.95B	-2.50B	-1.58B	-1.15B	-740.49M
Balance Sheet
Total Assets	7.38B	8.17B	9.09B	9.10B	9.22B	7.82B
Cash, Cash Equivalents and Short-Term Investments	2.30B	2.74B	3.12B	4.95B	7.38B	6.33B
Total Debt	2.36B	2.35B	1.88B	1.20B	382.62M	436.75M
Total Liabilities	2.84B	2.87B	2.32B	1.46B	545.18M	608.23M
Stockholders Equity	4.54B	5.30B	6.70B	7.37B	8.67B	7.21B
Cash Flow
Free Cash Flow	-2.67B	-3.19B	-3.69B	-1.59B	-1.10B	-743.60M
Operating Cash Flow	-2.11B	-2.39B	-2.03B	-1.26B	-1.03B	-539.26M
Investing Cash Flow	79.45M	-659.66M	-1.63B	-3.24B	199.68M	1.02B
Financing Cash Flow	2.39B	2.96B	1.85B	919.16M	1.48B	5.35B

Polaris Group Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6550 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:4157	52Neutral	TWD 5.78B	37.38	―	―	530.40%	―
TW:4174	48Neutral	TWD 7.23B	-2.37	―	―	-2.20%	29.08%
TW:6550	37Underperform	TWD 6.55B	-1.52	―	―	6.15%	-13.99%
TW:6499	33Underperform	TWD 7.33B	-16.44	―	―	69.62%	59.41%

* General Sector Average

Performance Comparison

TW:6550 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6550	Polaris Group	13.50	-44.44	-76.70%
TW:4157	TaiGen Biopharmaceuticals Holdings Limited	8.22	-1.24	-13.11%
TW:4174	OBI Pharma, Inc.	64.90	15.10	30.32%
TW:6499	Medeon Biodesign, Inc.	72.40	-24.10	-24.97%
TW:6891	Locus Cell Co., Ltd.	36.85	7.05	23.66%
TW:6976	Acepodia, Inc.	11.90	-3.40	-22.22%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Polaris Group AI Stock Analysis